Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
343 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Ulcerative Colitis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Ulcerative Colitis - Pipeline Review, H2 2014', provides an overview of the Ulcerative Colitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ulcerative Colitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ulcerative Colitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Ulcerative Colitis Overview 11 Therapeutics Development 12 Pipeline Products for Ulcerative Colitis - Overview 12 Pipeline Products for Ulcerative Colitis - Comparative Analysis 13 Ulcerative Colitis - Therapeutics under Development by Companies 14 Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes 20 Ulcerative Colitis - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Ulcerative Colitis - Products under Development by Companies 25 Ulcerative Colitis - Products under Investigation by Universities/Institutes 32 Ulcerative Colitis - Companies Involved in Therapeutics Development 33 Ajinomoto Pharmaceuticals Co., Ltd. 33 AlphaMab Co., Ltd 34 Altheus Therapeutics, Inc. 35 Am-Pharma B.V. 36 Amgen Inc. 37 Astellas Pharma Inc. 38 AstraZeneca PLC 39 Athersys, Inc. 40 Atlantic Healthcare plc 41 Avaxia Biologics, Inc. 42 Biocon Limited 43 BioLineRx, Ltd. 44 Bristol-Myers Squibb Company 45 Celgene Corporation 46 Celltrion, Inc. 47 ChironWells GmbH 48 Coronado Biosciences, Inc. 49 Cosmo Pharmaceuticals S.p.A 50 Dr. Falk Pharma GmbH 51 Drais Pharmaceuticals, Inc. 52 Effimune SAS 53 Emergent BioSolutions Inc. 54 Enceladus Pharmaceuticals BV 55 Epirus Biopharmaceuticals, Inc. 56 Euroscreen S.A. 57 Farmacija d.o.o. Tuzla 58 Flexion Therapeutics, Inc. 59 Galapagos NV 60 Genentech, Inc. 61 Genfit SA 62 Genor BioPharma Co., Ltd. 63 Gilead Sciences, Inc. 64 GlaxoSmithKline plc 65 GT Biologics Limited 66 GW Pharmaceuticals plc 67 Harbor Therapeutics, Inc. 68 iCo Therapeutics Inc. 69 InDex Pharmaceuticals AB 70 INOXIA Lifesciences GmbH 71 Invion Limited 72 Johnson & Johnson 73 Kaken Pharmaceutical Co., Ltd. 74 LIPID THERAPEUTICS GmbH 75 LTT Bio-Pharma Co., Ltd. 76 Medestea Research & Production S.p.A. 77 Morphotek, Inc. 78 NasVax Ltd. 79 Nogra Pharma Limited 80 Oncobiologics, Inc. 81 Pfizer Inc. 82 Pluristem Therapeutics Inc. 83 ProtAb Ltd 84 Qu Biologics Inc. 85 Receptos, Inc. 86 Sandoz Inc. 87 Sanofi 88 Sigmoid Pharma Limited 89 Stelic Institute & Co. 90 sterna biologicals Gmbh & Co KG 91 Synergy Pharmaceuticals, Inc. 92 Takeda Pharmaceutical Company Limited 93 TiGenix NV 94 Tillotts Pharma AG 95 Trino Therapeutics Ltd 96 Vascular Biogenics Ltd. 97 Ventria Bioscience 98 Zyngenia, Inc. 99 Ulcerative Colitis - Therapeutics Assessment 100 Assessment by Monotherapy Products 100 Assessment by Combination Products 101 Assessment by Target 102 Assessment by Mechanism of Action 106 Assessment by Route of Administration 109 Assessment by Molecule Type 111 Drug Profiles 113 (mesalamine + N-acetylcysteine) - Drug Profile 113 (metenkefalin + tridecactide) - Drug Profile 115 AB-0045 - Drug Profile 116 abrilumab - Drug Profile 117 ABS-11 - Drug Profile 119 adalimumab biosimilar - Drug Profile 120 adalimumab biosimilar - Drug Profile 122 adalimumab biosimilar - Drug Profile 123 adalimumab biosimilar - Drug Profile 124 adalimumab biosimilar - Drug Profile 125 adalimumab biosimilar - Drug Profile 126 adalimumab biosimilar - Drug Profile 127 adalimumab biosimilar - Drug Profile 128 adalimumab biosimilar - Drug Profile 129 AJM-300 - Drug Profile 130 alicaforsen sodium - Drug Profile 132 Anatabine - Drug Profile 133 Anti-CD3 Oral Immunotherapy - Drug Profile 134 Antibodies to Target Metallothioneins for Ulcerative Colitis and Crohns Disease - Drug Profile 136 apremilast - Drug Profile 137 ASP-3291 - Drug Profile 139 AVX-470 - Drug Profile 140 AW/EPO-002 - Drug Profile 141 AW/EPO-003 - Drug Profile 142 AW/EPOPD-01 - Drug Profile 143 AW/EPOPD-02 - Drug Profile 144 AW/EPOPD-06 - Drug Profile 145 bertilimumab - Drug Profile 146 BL-7040 - Drug Profile 148 BLI-1006 - Drug Profile 151 budesonide - Drug Profile 152 budesonide ER - Drug Profile 155 budesonide ER - Drug Profile 157 CNDO-201 - Drug Profile 159 Cx-602 - Drug Profile 161 cyclosporine CR - Drug Profile 162 DIMS-0150 - Drug Profile 163 Drugs for Ulcerative Colitis - Drug Profile 165 Drugs to Inhibit TNFR25 for Gastrointestinal Disorders - Drug Profile 166 eldelumab - Drug Profile 167 enalaprilat - Drug Profile 169 ES-210 - Drug Profile 171 ESN-282 - Drug Profile 172 etrolizumab - Drug Profile 173 FX-003 - Drug Profile 175 GED-0507 - Drug Profile 176 GFT-505 - Drug Profile 177 GLPG-0974 - Drug Profile 180 GS-5745 - Drug Profile 181 GSK-1399686 - Drug Profile 182 GWP-42003 - Drug Profile 183 HE-3286 - Drug Profile 185 hyaluronate sodium - Drug Profile 187 IAC VITA - Drug Profile 188 infliximab - Drug Profile 190 infliximab biosimilar - Drug Profile 192 infliximab biosimilar - Drug Profile 194 infliximab biosimilar - Drug Profile 195 INV-103 - Drug Profile 196 INV-88 - Drug Profile 198 KAG-308 - Drug Profile 199 KANAb-071 - Drug Profile 200 Leukothera - Drug Profile 201 Low Molecular Weight Heparin - Drug Profile 202 LT-02 - Drug Profile 203 MD-707 - Drug Profile 204 mesalamine - Drug Profile 205 mesalamine - Drug Profile 206 mesalamine CR - Drug Profile 207 mesalamine ER - Drug Profile 208 Monoclonal Antibody to Inhibit Ang-2 and TNF-a for Ulcerative Colitis and Inflammatory Disease - Drug Profile 210 MultiStem - Drug Profile 211 naltrexone - Drug Profile 214 Nanocort - Drug Profile 215 ONS-3015 - Drug Profile 217 PC-SOD - Drug Profile 218 peficitinib - Drug Profile 219 Peptides to Inhibit IL-1 Beta for Ulcerative Colitis and Crohn's Disease - Drug Profile 220 PF-00547659 - Drug Profile 221 PH-44 - Drug Profile 223 PH-46A - Drug Profile 224 PH-5 - Drug Profile 225 Prozumab - Drug Profile 226 QBECO - Drug Profile 227 Recombinant Human Alkaline Phosphatase - Drug Profile 229 Rosburix - Drug Profile 231 RPC-1063 - Drug Profile 232 SAR-252067 - Drug Profile 234 SB-012 - Drug Profile 235 SD-010 - Drug Profile 236 Small Molecule for Ulcerative Colitis and Inflammation - Drug Profile 237 Small Molecule to Agonize OP3 Receptor for Inflammatory Bowel Diseases - Drug Profile 238 Small Molecules for Gastrointestinal Disorders - Drug Profile 239 Small Molecules to Inhibit IL-13 for Inflammatory Bowel Disease and Ulcerative Colitis - Drug Profile 240 Small Molecules to Target IL-13 for Inflammatory Bowel Disease and Ulcerative Colitis - Drug Profile 241 SP-333 - Drug Profile 242 Stem Cell Therapy for Inflammatory Bowel Disease - Drug Profile 243 STNM-01 - Drug Profile 244 TAK-114 - Drug Profile 245 tofacitinib - Drug Profile 247 VB-201 - Drug Profile 251 VEDA-1209 - Drug Profile 253 vedolizumab - Drug Profile 254 VEN-120 - Drug Profile 256 Ulcerative Colitis - Recent Pipeline Updates 257 Ulcerative Colitis - Dormant Projects 323 Ulcerative Colitis - Discontinued Products 326 Ulcerative Colitis - Product Development Milestones 327 Featured News & Press Releases 327 Appendix 335 Methodology 335 Coverage 335 Secondary Research 335 Primary Research 335 Expert Panel Validation 335 Contact Us 336 Disclaimer 336
List of Tables Number of Products under Development for Ulcerative Colitis, H2 2014 19 Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H2 2014 20 Number of Products under Development by Companies, H2 2014 22 Number of Products under Development by Companies, H2 2014 (Contd..1) 23 Number of Products under Development by Companies, H2 2014 (Contd..2) 24 Number of Products under Development by Companies, H2 2014 (Contd..3) 25 Number of Products under Development by Companies, H2 2014 (Contd..4) 26 Number of Products under Investigation by Universities/Institutes, H2 2014 27 Comparative Analysis by Late Stage Development, H2 2014 28 Comparative Analysis by Clinical Stage Development, H2 2014 29 Comparative Analysis by Early Stage Development, H2 2014 30 Comparative Analysis by Unknown Stage Development, H2 2014 31 Products under Development by Companies, H2 2014 32 Products under Development by Companies, H2 2014 (Contd..1) 33 Products under Development by Companies, H2 2014 (Contd..2) 34 Products under Development by Companies, H2 2014 (Contd..3) 35 Products under Development by Companies, H2 2014 (Contd..4) 36 Products under Development by Companies, H2 2014 (Contd..5) 37 Products under Development by Companies, H2 2014 (Contd..6) 38 Products under Investigation by Universities/Institutes, H2 2014 39 Ulcerative Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H2 2014 40 Ulcerative Colitis - Pipeline by AlphaMab Co., Ltd, H2 2014 41 Ulcerative Colitis - Pipeline by Altheus Therapeutics, Inc., H2 2014 42 Ulcerative Colitis - Pipeline by Am-Pharma B.V., H2 2014 43 Ulcerative Colitis - Pipeline by Amgen Inc., H2 2014 44 Ulcerative Colitis - Pipeline by Astellas Pharma Inc., H2 2014 45 Ulcerative Colitis - Pipeline by AstraZeneca PLC, H2 2014 46 Ulcerative Colitis - Pipeline by Athersys, Inc., H2 2014 47 Ulcerative Colitis - Pipeline by Atlantic Healthcare plc, H2 2014 48 Ulcerative Colitis - Pipeline by Avaxia Biologics, Inc., H2 2014 49 Ulcerative Colitis - Pipeline by Biocon Limited, H2 2014 50 Ulcerative Colitis - Pipeline by BioLineRx, Ltd., H2 2014 51 Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Company, H2 2014 52 Ulcerative Colitis - Pipeline by Celgene Corporation, H2 2014 53 Ulcerative Colitis - Pipeline by Celltrion, Inc., H2 2014 54 Ulcerative Colitis - Pipeline by ChironWells GmbH, H2 2014 55 Ulcerative Colitis - Pipeline by Coronado Biosciences, Inc., H2 2014 56 Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2014 57 Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H2 2014 58 Ulcerative Colitis - Pipeline by Drais Pharmaceuticals, Inc., H2 2014 59 Ulcerative Colitis - Pipeline by Effimune SAS, H2 2014 60 Ulcerative Colitis - Pipeline by Emergent BioSolutions Inc., H2 2014 61 Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H2 2014 62 Ulcerative Colitis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 63 Ulcerative Colitis - Pipeline by Euroscreen S.A., H2 2014 64 Ulcerative Colitis - Pipeline by Farmacija d.o.o. Tuzla, H2 2014 65 Ulcerative Colitis - Pipeline by Flexion Therapeutics, Inc., H2 2014 66 Ulcerative Colitis - Pipeline by Galapagos NV, H2 2014 67 Ulcerative Colitis - Pipeline by Genentech, Inc., H2 2014 68 Ulcerative Colitis - Pipeline by Genfit SA, H2 2014 69 Ulcerative Colitis - Pipeline by Genor BioPharma Co., Ltd., H2 2014 70 Ulcerative Colitis - Pipeline by Gilead Sciences, Inc., H2 2014 71 Ulcerative Colitis - Pipeline by GlaxoSmithKline plc, H2 2014 72 Ulcerative Colitis - Pipeline by GT Biologics Limited, H2 2014 73 Ulcerative Colitis - Pipeline by GW Pharmaceuticals plc, H2 2014 74 Ulcerative Colitis - Pipeline by Harbor Therapeutics, Inc., H2 2014 75 Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H2 2014 76 Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H2 2014 77 Ulcerative Colitis - Pipeline by INOXIA Lifesciences GmbH, H2 2014 78 Ulcerative Colitis - Pipeline by Invion Limited, H2 2014 79 Ulcerative Colitis - Pipeline by Johnson & Johnson, H2 2014 80 Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2014 81 Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H2 2014 82 Ulcerative Colitis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2014 83 Ulcerative Colitis - Pipeline by Medestea Research & Production S.p.A., H2 2014 84 Ulcerative Colitis - Pipeline by Morphotek, Inc., H2 2014 85 Ulcerative Colitis - Pipeline by NasVax Ltd., H2 2014 86 Ulcerative Colitis - Pipeline by Nogra Pharma Limited, H2 2014 87 Ulcerative Colitis - Pipeline by Oncobiologics, Inc., H2 2014 88 Ulcerative Colitis - Pipeline by Pfizer Inc., H2 2014 89 Ulcerative Colitis - Pipeline by Pluristem Therapeutics Inc., H2 2014 90 Ulcerative Colitis - Pipeline by ProtAb Ltd, H2 2014 91 Ulcerative Colitis - Pipeline by Qu Biologics Inc., H2 2014 92 Ulcerative Colitis - Pipeline by Receptos, Inc., H2 2014 93 Ulcerative Colitis - Pipeline by Sandoz Inc., H2 2014 94 Ulcerative Colitis - Pipeline by Sanofi, H2 2014 95 Ulcerative Colitis - Pipeline by Sigmoid Pharma Limited, H2 2014 96 Ulcerative Colitis - Pipeline by Stelic Institute & Co., H2 2014 97 Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2014 98 Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals, Inc., H2 2014 99 Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 100 Ulcerative Colitis - Pipeline by TiGenix NV, H2 2014 101 Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H2 2014 102 Ulcerative Colitis - Pipeline by Trino Therapeutics Ltd, H2 2014 103 Ulcerative Colitis - Pipeline by Vascular Biogenics Ltd., H2 2014 104 Ulcerative Colitis - Pipeline by Ventria Bioscience, H2 2014 105 Ulcerative Colitis - Pipeline by Zyngenia, Inc., H2 2014 106 Assessment by Monotherapy Products, H2 2014 107 Assessment by Combination Products, H2 2014 108 Number of Products by Stage and Target, H2 2014 110 Number of Products by Stage and Mechanism of Action, H2 2014 114 Number of Products by Stage and Route of Administration, H2 2014 117 Number of Products by Stage and Molecule Type, H2 2014 119 Ulcerative Colitis Therapeutics - Recent Pipeline Updates, H2 2014 264 Ulcerative Colitis - Dormant Projects, H2 2014 330 Ulcerative Colitis - Discontinued Products, H2 2014 333
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
